Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Purevax RCP FeLV   
Auth. number : EU/2/04/048
Active substance : Not available
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI06 - Immunologicals for felidae
Pharmacological subgroup: QI06A - Cat
Chemical subgroup: QI06AH - Live and inactivated viral vaccines
Chemical substance: QI06AH - Live and inactivated viral vaccines
(See WHO ATCvet Index)
Indication: Active immunisation of cats aged 8 weeks and older:

- against feline viral rhinotracheitis to reduce clinical signs,
- against calicivirus infection to reduce clinical signs,
- against feline panleucopenia to prevent mortality and clinical signs,
- against leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.

The duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the feline leukaemia component
Marketing Authorisation Holder: Merial
29 avenue Tony Garnier, 69007 Lyon, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/02/2005 Centralised - Authorisation EMEA/V/C/89 (2005)471 of 23/02/2005
18/07/2005 Centralised - Variation (no change in Commission Decision) EMEA/V/C/89/II/1
25/01/2008 Centralised - Variation EMEA/V/C/89/II/2, 3, 4 (2008)336 of 22/01/2008
22/09/2008 Centralised - Variation (no change in Commission Decision) EMEA/V/C/89/II/5
17/02/2009 Centralised - Variation EMEA/V/C/89/II/6 (2009)1125 of 13/02/2009
19/01/2010 Centralised - Renewal EMEA/V/C/89/R/7 (2010)166 of 15/01/2010
15/01/2015 Centralised - Variation EMEA/V/C/89/WS/606
Updated with Decision(2016)1689 of 15/03/2016
17/03/2016 Centralised - Yearly update (2016)1689 of 15/03/2016